XLO (XLO) Stock Price & Analysis
XLO (XLO) fell 1.00% to USD 8.91 as of September 9, 2026 at 00:49 UTC, according to Nexqual real-time market data.
XLO last closed at USD 9; the session ranged USD 8.81–9.1 on volume of 9,993 shares. Market capitalization is $58.63M, with a 52-week range of USD 6.47–12.74 (NCM). Source: Nexqual, September 9, 2026 at 00:49 UTC.
Key Statistics (as of September 9, 2026 at 00:49 UTC)
| Price | USD 8.91 |
|---|---|
| Change | ▼ 1.00% (down) |
| Previous Close | USD 9 |
| Open | USD 8.98 |
| Day Range | USD 8.81 – 9.1 |
| 52-Week Range | USD 6.47 – 12.74 |
| Volume | 9,993 shares |
| Market Cap | $58.63M |
| Exchange | NCM |
Technical Analysis (XLO)
Nexqual's technical model rates XLO "SELL" based on 1 bullish and 4 bearish signals across 126 daily candles, as of September 9, 2026 at 00:49 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.36 (neutral) |
| vs SMA50 | Below (USD 9.09) |
| MACD | -0.03 (negative) |
Analyst Ratings (XLO)
Wall Street analysts rate XLO "None" based on 1 analysts, with a mean price target of USD 20 (range USD 20–20), per Nexqual as of September 9, 2026 at 00:49 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 20 |
| High Target | USD 20 |
| Low Target | USD 20 |
| Buy / Hold / Sell | 1 / 0 / 0 |
Earnings (XLO)
| Revenue Estimate | $4.84M |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.33 vs est -0.59 ▲ beat |
| 2025-09-30 | USD -1.54 vs est -0.42 ▼ miss |
Source: Nexqual, September 9, 2026 at 00:49 UTC.
Financials & Fundamentals (XLO)
| Total Revenue | $64.09M |
|---|---|
| Revenue Growth (YoY) | +131.20% |
| Gross Margin | +83.16% |
| Operating Margin | -18.68% |
| Profit Margin | -34.06% |
| ROE | -55.03% |
| Debt / Equity | 8.72 |
| Current Ratio | 4.25 |
| Total Cash | $136.04M |
| Total Debt | $6.30M |
| Free Cash Flow | $-37.56M |
Source: Nexqual, September 9, 2026 at 00:49 UTC.
Financial Health Score (XLO)
Nexqual rates XLO's overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 00:49 UTC.
| Growth | Strong — Revenue +590% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $136M cash vs $6M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$38M, burning cash |
| Efficiency | Critical — ROE -55%, ROA -13.6% |
Ownership (XLO)
| Insider Ownership | +25.98% |
|---|---|
| Institutional Ownership | +50.14% |
| Shares Outstanding | 6.58M |
| Float | 3.40M |
| Short % of Float | +7.16% |
Source: Nexqual, September 9, 2026 at 00:49 UTC.
Leadership (XLO)
XLO is led by Rene Russo BCPS, Pharm.D. (age 50), President, CEO & Director, per Nexqual as of September 9, 2026 at 00:49 UTC.
| President, CEO & Director | Rene Russo BCPS, Pharm.D. (age 50) |
|---|---|
| CFO & COO | Christopher Frankenfield (age 43) |
| Senior Vice President of Finance & Accounting | Kevin M. Brennan (age 55) |
| Chief Scientific Officer | Uli Bialucha |
| Senior Vice President of Medical Affairs | Ruth du Moulin |
Major Backers & Investors (XLO)
Notable institutional backers of XLO include Bain Capital Life Sciences Investors, LLC, Gilead Sciences Inc, Orbimed Advisors LLC., according to Nexqual as of September 9, 2026 at 00:49 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bain Capital Life Sciences Investors, LLC | 10.09% |
| Gilead Sciences Inc | 9.88% |
| Orbimed Advisors LLC. | 9% |
| Frazier Life Sciences Management, L.P. | 6.42% |
| Stonepine Capital Management, LLC | 3.43% |
| Sio Capital Management, LLC | 2.32% |
| Adage Capital Partners GP L.L.C. | 1.7% |
| Merck & Co., Inc. | 1.61% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.42% |
Source: Nexqual, September 9, 2026 at 00:49 UTC.
From XLO's Latest SEC 10-K Filing (filed 2026-03-23)
Source: SEC EDGAR 10-K. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RLYB | Rallybio Corporation | USD 16.61 | ▼ 1.57% |
| TYRA | Tyra Biosciences, Inc. | USD 26.73 | ▲ 7.52% |
| INAB | IN8bio, Inc. | USD 1.14 | ▼ 1.72% |
| HOWL | Werewolf Therapeutics, Inc. | USD 0.98 | ▲ 3.81% |
| AVTX | Avalo Therapeutics, Inc. | USD 19.71 | ▲ 3.74% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 00:49 UTC. This page is informational and not investment advice.